Physician profile
William J Ryan
NPI 1841271319
$1,383.57
in general payments reported to CMS, 2019-2025
9 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $363 · 2023: $295 · 2024: $271 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813 · Education: $40.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.84 |
| Education | $40.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $500.86 | 2022-2024 | Breztri, Tezspire |
| Glaxosmithkline, LLC. | $353.06 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $129.31 | 2025 | Inspire |
| Harmony Biosciences LLC | $124.99 | 2021 | |
| Pulmonx Corporation | $115.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.99 | 2025 | Ofev |
| Insmed, INC. | $33.14 | 2023-2024 | Arikayce |
| United Therapeutics Corporation | $26.30 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.